Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Collateral Therapeutics (CLTX) -- Ignore unavailable to you. Want to Upgrade?

To: Silver Knife who wrote (1)	3/8/1999 9:18:00 PM
From: Silver Knife	Read Replies (1) \| Respond to of 35

I have not invested in CLTX yet. It's is up about 3 dollars in the past month but closed down 3/8 to 9 1/8. "Angiogenesis" is one of the hottest new areas in cardiac research. CLTX appears to have financial backing from Schering. Does anyone know any other companies doing this kind of research?

To: Silver Knife who wrote (1)	4/1/1999 8:09:00 PM
From: Jibacoa	Read Replies (1) \| Respond to of 35

The stock today had a nice run, going through the previous "triple top" it formed with the highs in early December, Mid-January and late February. Was there any news? The home-page looks good. How about the "financials" ? I guess at present "internet conditioned times" that is an "unimportant matter" It seems the stock may come back to re-test the 9 3/4 area before continuing its upward ride. I noticed yesterday that Immune Response also has some news on their " gene treatment" of hemophilia, although their research on phase one was on mice. I guess if we start getting some "good news" on some of the "gene therapies" some of these biotecs doing "gene research" may become a hot commodity. Good luck to you.